Featured News
Bring Safer, Smarter Therapies to Patients Faster
Discover the impact organoids are having on drug development
Imagine a world where medicines are safer, more effective, and reach patients faster. Charles River is making that vision a reality with organoids – miniature, lab-made models of human organs that closely mimic how real organs respond to drugs.
These advanced models allow researchers to detect potential side effects and pinpoint therapeutic effects earlier in the development journey, before a drug reaches clinical trials. At our Leiden, Netherlands, facility, gut organoids recently identified antiviral compounds that traditional animal models missed, saving valuable time, resources, and potentially lives. This means stronger preclinical data, fewer surprises in late-stage trials, and faster regulatory approval. More importantly, this means safer, more personalized treatments for patients.
In a recent Nature Springer feature, we expand on how organoid-based testing improves decision-making, reduces clinical failures, and supports the FDA’s shift from traditional animal models.
LSX World Congress
Charles River joins LSX USA 2025 to present on New Approach Methodologies (NAMs)—advancing innovation, investment, and partnerships in the future of healthcare.
View the event